S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
Laser breakthrough could send stock soaring 2,467% (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
Laser breakthrough could send stock soaring 2,467% (Ad)
MarketBeat Week in Review – 9/25 - 9/29
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
The single greatest medical breakthrough of all time? (Ad)
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Apple says it will fix software problems blamed for making iPhone 15 models too hot to handle
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
Laser breakthrough could send stock soaring 2,467% (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
Laser breakthrough could send stock soaring 2,467% (Ad)
MarketBeat Week in Review – 9/25 - 9/29
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
The single greatest medical breakthrough of all time? (Ad)
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Apple says it will fix software problems blamed for making iPhone 15 models too hot to handle
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
Laser breakthrough could send stock soaring 2,467% (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
Laser breakthrough could send stock soaring 2,467% (Ad)
MarketBeat Week in Review – 9/25 - 9/29
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
The single greatest medical breakthrough of all time? (Ad)
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Apple says it will fix software problems blamed for making iPhone 15 models too hot to handle
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
Laser breakthrough could send stock soaring 2,467% (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
Laser breakthrough could send stock soaring 2,467% (Ad)
MarketBeat Week in Review – 9/25 - 9/29
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
The single greatest medical breakthrough of all time? (Ad)
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Apple says it will fix software problems blamed for making iPhone 15 models too hot to handle
OTCMKTS:SRNEQ

Sorrento Therapeutics (SRNEQ) Stock Forecast, Price & News

$0.09
-0.01 (-9.62%)
(As of 09/29/2023 ET)
Compare
Today's Range
$0.09
$0.12
50-Day Range
$0.09
$0.35
52-Week Range
$0.09
$1.89
Volume
3.50 million shs
Average Volume
3.12 million shs
Market Capitalization
$51.82 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

SRNEQ stock logo

About Sorrento Therapeutics (OTCMKTS:SRNEQ) Stock

Sorrento Therapeutics Inc is a clinical-stage biopharmaceutical company based in San Diego, California. The company specializes in developing antibody-based therapies for cancer, autoimmune diseases, and chronic pain. Sorrento Therapeutics was founded in 1989 and has since grown into a  player in the biopharmaceutical industry, focusing on developing innovative and personalized therapies for patients.

The management team at Sorrento Therapeutics is led by Dr. Henry Ji, who serves as the company's Chairman and CEO. Dr. Ji has over 20 years of experience in the biopharmaceutical industry and has played a vital role in developing innovative Sorrento Therapeutics therapies. Other notable team members are Mike Royal, Chief Medical Officer, who has over 20 years of clinical development experience and Dr. Robert D. Allen, who has over 15 years of biotechnology industry research and preclinical development experience. 

Over the past few years, Sorrento Therapeutics has reported relevant growth in revenue. However, the company has also reported significant losses increasing year over year. The company's debt levels have varied dramatically, with assets and liabilities increasing year over year. Sorrento Therapeutics has undergone substantial changes in ownership over the past few years, with several prominent investors increasing their stakes in the company. Sorrento Therapeutics' valuation metrics align with industry peers, with a price-to-book ratio near industry averages. However, the company's price-to-earnings ratio is currently negative, typical for clinical-stage biopharmaceutical companies that have yet to reach profitability. Sorrento Therapeutics stock has been volatile in recent years, with significant price movements and changes in trading volume. The company's stock price has steadily declined over the past five years.

The biopharmaceutical industry is highly competitive, with many large, established companies and smaller, innovative players like Sorrento Therapeutics. High research and development spending levels, lengthy regulatory approval processes, and significant intellectual property protections characterize the industry. Sorrento Therapeutics faces competition from established players such as Pfizer, Merck, and Bristol-Myers Squibb, as well as smaller biotechs developing similar antibody-based therapies.

Sorrento Therapeutics has several potential growth opportunities, including developing its proprietary antibodies and other therapies for treating cancer, autoimmune diseases, and chronic pain. The company is also exploring partnerships and collaborations with other companies in the biopharmaceutical industry to help accelerate the development of its pipeline of therapies. Additionally, Sorrento Therapeutics is expanding into new markets, focusing on Asia, with significant demand for innovative treatments.

The biopharmaceutical industry is highly regulated, and Sorrento Therapeutics may face challenges in obtaining regulatory approval for its therapies. The company's financial performance has also been volatile, with significant losses reported in recent years. Sorrento Therapeutics will need to continue investing heavily in research and development to maintain its competitive position in the industry, which may strain the company's financial resources. In addition, the biopharmaceutical industry is subject to significant geopolitical and regulatory risks, which could impact Sorrento Therapeutics' operations and growth prospects.

SRNEQ Price History

SRNEQ Stock News Headlines

Better Than Oil Stocks?
The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment.
Better Than Oil Stocks?
The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment.
Sorrento Therapeutics Inc. (SRNEQ)
Sorrento Therapeutics Inc (SRNEQ)
See More Headlines
Receive SRNEQ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sorrento Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SRNEQ Company Calendar

Last Earnings
8/11/2023
Today
9/30/2023
Next Earnings (Estimated)
10/30/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:SRNEQ
Employees
949
Year Founded
N/A

Profitability

Net Income
$-572,840,000.00
Net Margins
-852.82%
Pretax Margin
-1,096.44%

Debt

Sales & Book Value

Annual Sales
$62.84 million
Book Value
($0.05) per share

Miscellaneous

Free Float
536,948,000
Market Cap
$51.82 million
Optionable
Optionable
Beta
2.23
The Best High-Yield Dividend Stocks for 2023 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Dr. Henry H. Ji Ph.D. (Age 59)
    Chairman, Pres & CEO
    Comp: $2.03M
  • Mr. Brian Cooley
    Sr. VP of Corp. Communications & Lymphatic Drug Devel. BU
  • Dr. Michael A. Royal J.D. (Age 69)
    M.D., MBA, SVP & Chief Medical Officer
  • Dr. Alexis Nahama D.V.M.
    Sr. VP of Neurotherapeutics BU
  • Dr. Mark R. Brunswick
    Sr. VP of Regulatory Affairs
  • Dr. Shawn Sahebi Ph.D.
    Sr. VP of Commercial Operations
  • Dr. Xiao Xu M.D.
    Pres of ACEA













SRNEQ Stock - Frequently Asked Questions

How have SRNEQ shares performed in 2023?

Sorrento Therapeutics' stock was trading at $0.3051 at the start of the year. Since then, SRNEQ shares have decreased by 69.2% and is now trading at $0.0940.
View the best growth stocks for 2023 here
.

When is Sorrento Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, October 30th 2023.
View our SRNEQ earnings forecast
.

How were Sorrento Therapeutics' earnings last quarter?

Sorrento Therapeutics, Inc. (OTCMKTS:SRNEQ) issued its earnings results on Friday, August, 11th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by $0.02. The company earned $15.03 million during the quarter. Sorrento Therapeutics had a negative trailing twelve-month return on equity of 1,999.61% and a negative net margin of 852.82%.

What is Sorrento Therapeutics' stock symbol?

Sorrento Therapeutics trades on the OTCMKTS under the ticker symbol "SRNEQ."

How do I buy shares of Sorrento Therapeutics?

Shares of SRNEQ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Sorrento Therapeutics' stock price today?

One share of SRNEQ stock can currently be purchased for approximately $0.09.

How much money does Sorrento Therapeutics make?

Sorrento Therapeutics (OTCMKTS:SRNEQ) has a market capitalization of $51.82 million and generates $62.84 million in revenue each year.

How many employees does Sorrento Therapeutics have?

The company employs 949 workers across the globe.

How can I contact Sorrento Therapeutics?

Sorrento Therapeutics' mailing address is 4955 DIRECTORS PLACE, SAN DIEGO CA, 92121. The official website for the company is www.sorrentotherapeutics.com. The company can be reached via phone at (858) 203-4100, via email at investors@sorrentotherapeutics.com, or via fax at 858-210-3759.

This page (OTCMKTS:SRNEQ) was last updated on 9/30/2023 by MarketBeat.com Staff

My Account -